S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Get Your Cash Out of U.S. Banks Immediately (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Get Your Cash Out of U.S. Banks Immediately (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Get Your Cash Out of U.S. Banks Immediately (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Get Your Cash Out of U.S. Banks Immediately (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
NASDAQ:YMAB

Y-mAbs Therapeutics (YMAB) Stock Forecast, Price & News

$8.17
+0.04 (+0.49%)
(As of 06/9/2023 ET)
Compare
Today's Range
$8.00
$8.66
50-Day Range
$5.68
$10.34
52-Week Range
$2.70
$20.48
Volume
257,093 shs
Average Volume
314,901 shs
Market Capitalization
$356.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.67

Y-mAbs Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
67.3% Upside
$13.67 Price Target
Short Interest
Healthy
5.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.88mentions of Y-mAbs Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$981,791 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.94) to ($0.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

250th out of 987 stocks

Pharmaceutical Preparations Industry

112th out of 482 stocks


YMAB stock logo

About Y-mAbs Therapeutics (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMAB Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Q1 2023 Y-mAbs Therapeutics Inc Earnings Call
See More Headlines

YMAB Price History

YMAB Company Calendar

Last Earnings
5/08/2023
Today
6/10/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:YMAB
Fax
N/A
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.67
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+67.3%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
12 Analysts

Profitability

Net Income
$-95,570,000.00
Pretax Margin
-98.48%

Debt

Sales & Book Value

Annual Sales
$75.03 million
Book Value
$2.50 per share

Miscellaneous

Free Float
34,287,000
Market Cap
$356.85 million
Optionable
Not Optionable
Beta
0.77

Key Executives

  • Thomas Gad
    President, Chief Executive Officer & Director
  • Joris Wiel Jan Wilms
    Chief Operating Officer & Senior Vice President
  • Bo Kruse
    CFO, Secretary. Treasurer & Executive VP
  • Torben Lund-Hansen
    Chief Technology Officer & Senior Vice President
  • Steen Lisby
    Chief Scientific Officer & Senior Vice President













YMAB Stock - Frequently Asked Questions

Should I buy or sell Y-mAbs Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 2 sell ratings, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares.
View YMAB analyst ratings
or view top-rated stocks.

What is Y-mAbs Therapeutics' stock price forecast for 2023?

12 Wall Street research analysts have issued twelve-month target prices for Y-mAbs Therapeutics' stock. Their YMAB share price forecasts range from $4.00 to $27.00. On average, they anticipate the company's stock price to reach $13.67 in the next year. This suggests a possible upside of 67.3% from the stock's current price.
View analysts price targets for YMAB
or view top-rated stocks among Wall Street analysts.

How have YMAB shares performed in 2023?

Y-mAbs Therapeutics' stock was trading at $4.88 at the beginning of 2023. Since then, YMAB shares have increased by 67.4% and is now trading at $8.17.
View the best growth stocks for 2023 here
.

When is Y-mAbs Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our YMAB earnings forecast
.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) announced its quarterly earnings data on Monday, May, 8th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.16. The business earned $20.30 million during the quarter, compared to analysts' expectations of $15.55 million. Y-mAbs Therapeutics had a negative net margin of 98.48% and a negative trailing twelve-month return on equity of 64.77%. The business's revenue for the quarter was up 93.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.64) EPS.

What ETFs hold Y-mAbs Therapeutics' stock?

ETFs with the largest weight of Y-mAbs Therapeutics (NASDAQ:YMAB) stock in their portfolio include IQ Chaikin U.S. Small Cap ETF (CSML).Principal Healthcare Innovators ETF (BTEC).

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.41%), State Street Corp (1.75%), Geode Capital Management LLC (1.52%), AIGH Capital Management LLC (0.98%), Acadian Asset Management LLC (0.91%) and Charles Schwab Investment Management Inc. (0.54%). Insiders that own company stock include Biotech Aps Wg, Bo Kruse, David N Gill, Johan Wedell-Wedellsborg, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends
.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $8.17.

How much money does Y-mAbs Therapeutics make?

Y-mAbs Therapeutics (NASDAQ:YMAB) has a market capitalization of $356.85 million and generates $75.03 million in revenue each year. The company earns $-95,570,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

How many employees does Y-mAbs Therapeutics have?

The company employs 148 workers across the globe.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The official website for the company is www.ymabs.com. The company can be reached via phone at (646) 885-8505 or via email at info@ymabs.com.

This page (NASDAQ:YMAB) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -